Ann: Notification of upcoming expiry of Unlisted Options, page-88

ok well it’s all down to data so we’ll see how this all comes out in the wash when trial completes in 2026 or whenever. But I’ll leave you with this “substance” , you can check this out for yourself, all discoverable online :
1. BMS 813160- potent CCR2/5 inhibitor , DKD- terminated in phase 2
2. PF 04634817 (Pfizer) - ccr2/5 inhibitor , DKD- abandoned after phase 2, only slightly better than placebo , efficacy not considered good enough
3. CCX140- potent selective ccr2 inhibitor - abandoned after weak result in FSGS trial. In DKD a modest 10-16% improvement vs placebo. No further development can be found.
And DIMX best result seen so far 17% over placebo in FSGS, null effect over placebo DKD
So chemokine ccr2 inhibitors haven’t set the world alight in kidney disease have they…